BCM
IMGN

BluePath Capital Management’s Immunogen Inc IMGN Stock Holding History

BluePath Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,193
Closed -$34.8K – 340
2023
Q3 		$34.8K Buy
+2,193
New +$36.5K 0.03% 224

Other funds holding IMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

BluePath Capital Management's IMGN Position: Q4 2023 in Review

BluePath Capital Management sold out of Immunogen Inc (IMGN) in Q4 2023, closing a stake of 2,193 shares — an estimated $34.8K sold.

BluePath Capital Management first reported a position in IMGN in Q3 2023 and held it in 1 quarter. The position peaked at $34.8K in Q3 2023. 327 funds tracked by Wall St. Rank hold IMGN as of Q4 2023.

  • BluePath Capital Management reported no remaining Immunogen Inc position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 2,193 Immunogen Inc shares in Q4 2023, an estimated $34.8K.
  • BluePath Capital Management first reported a position in Immunogen Inc in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's Immunogen Inc position peaked at $34.8K in Q3 2023.
  • 327 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.